- Investing.com
Metrics to compare | BLLN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLLNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 157.1x | −11.8x | −0.3x | |
PEG Ratio | 1.25 | −1.32 | 0.00 | |
Price/Book | 9.7x | 9.0x | 2.6x | |
Price / LTM Sales | 13.1x | 0.9x | 2.8x | |
Upside (Analyst Target) | 16.8% | 15.4% | 67.2% | |
Fair Value Upside | Unlock | 15.9% | 10.1% | Unlock |
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.